MatthewAdrianSpearMD

Radiation Oncology • Rancho Santa Fe, CA

Physician

Join to view full profile

Dr. Spear is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Spear's full profile

Already have an account?

Office
PO box 1108
Rancho Santa Fe, CA 92067
Phone+1 858-352-8557
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1994 - 1997
University of HawaiiInternship, Transitional Year, 1993 - 1994
Stanford University School of MedicineClass of 1993

Certifications & Licensure

CA State Medical License 1998 - 2025
NC State Medical License 2011 - 2012

Clinical Trials

Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2006 Apr 01
Completed
Phase 1
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Feb 01
Completed
Phase 1, Phase 2
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Start of enrollment: 2016 Sep 22
Completed
Phase 1, Phase 2
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Start of enrollment: 2014 Sep 10
Terminated
Phase 1, Phase 2
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) Start of enrollment: 2017 Sep 20
Terminated
Phase 1, Phase 2
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Start of enrollment: 2018 Oct 29
Active, not recruiting
Phase 1
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Start of enrollment: 2020 Feb 28
Active, not recruiting
Phase 1
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

109 citations
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung can...
Michael Millward, Timothy J. Price, Amanda R. Townsend, Christopher Sweeney, Andrew Spencer, Shawgi Sukumaran, Angie M. Longenecker, Lonnie Lee, Ana Lay, Girish Sharma...> ;Investigational New Drugs. 2012 Dec 1
52 citations
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
Michael Millward, P. N. Mainwaring, Alain C. Mita, Kristine C. Federico, G. K. Lloyd, Natasha Reddinger, Steffan T. Nawrocki, Monica M. Mita, Matthew A. Spear> ;Investigational New Drugs. 2012 Jun 1
27 citations
Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Matthew A. Spear, Patricia LoRusso, Alain C. Mita, Monica M. Mita> ;Current Drug Targets. 2011 Nov 30
70 citations
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath, Kyriakos P. Papadopoulos, Kristine C. Federico, Steven Reich, Ofelia Romero, Lisa M...> ;Clinical Cancer Research. 2010 Dec 1
4 citations
Phase I/II study of IV topotecan in combination with whole brain radiation for the treatment of brain metastases
Alireza Mirmiran, Edward McClay, Matthew A Spear> ;Medical Oncology. 2007 Jan 1
9 citations
Focal radiation therapy of brain metastases after complete surgical resection
Gautam Bahl, G. White, John F. Alksne, Lakshmi Vemuri, Matthew A Spear> ;Medical Oncology. 2006 Jan 1
6 citations
Temozolomide and radiation for aggressive pediatric central nervous system malignancies.
Kenneth C Loh, Jennifer Willert, Hal S. Meltzer, William Roberts, Bryce A. Kerlin, Richard Kadota, Michael J. Levy, G. White, Amy Geddis, Deborah Schiff, Laura Martin,...> ;Journal of Pediatric Hematology/oncology. 2005 May 1
7 citations
Targeting HSV amplicon vectors.
Paola Grandi, Matthew A Spear, Xandra O. Breakefield, Sam Wang> ;Methods. 2004 Jun 1
31 citations
HSV-1 virions engineered for specific binding to cell surface receptors.
Paola Grandi, Sam Wang, Deborah E. Schuback, Victor Krasnykh, Matthew A Spear, David T. Curiel, Roberto Manservigi, Xandra O. Breakefield> ;Molecular Therapy. 2004 Mar 1
23 citations
Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter.
H. Hsu, Rainov Ng, Quinones A, Eling Dj, K.M. Sakamoto, Spear Ma> ;Anticancer Research. 2003 May 1
10 citations
HSV-1 amplicon peptide display vector.
Matthew A Spear, Deborah E. Schuback, Kenichi Miyata, Paola Grandi, Fang Sun, Linda Yoo, Anh T. Nguyen, Curtis R. Brandt, Xandra O. Breakefield> ;Journal of Virological Methods. 2003 Jan 1
33 citations
Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells
Matthew A Spear, Xandra O. Breakefield, James P. Beltzer, Deborah E. Schuback, Ralph Weissleder, Francisco S. Pardo, Robert C Ladner> ;Cancer Gene Therapy. 2001 Jul 1
38 citations
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined wit...
Matthew A Spear, F Sun, D J Eling, Elizabeth A. Gilpin, Thomas J. Kipps, E A Chiocca, Michael Bouvet> ;Cancer Gene Therapy. 2000 Jul 1
10 citations
Efficient DNA Subcloning through Selective Restriction Endonuclease Digestion
Matthew A Spear> ;Biotechniques. 2000 Apr 1
6 citations
Tolerance of autologous and allogeneic bone grafts to therapeutic radiation in humans.
Matthew A Spear, Damian E. Dupuy, Jenine J Park, Elkan F. Halpern, Ira J. Spiro> ;International Journal of Radiation Oncology, Biology, Physics. 1999 Dec 1
47 citations
Mapping the In Vivo Distribution of Herpes Simplex Virions
Dawid Schellingerhout, Alexei A. Bogdanov, Edgardo Marecos, Matthew A Spear, Xandra O. Breakefield, Ralph Weissleder> ;Human Gene Therapy. 1998 Jul 20
200 citations
Individualizing management of aggressive fibromatoses.
Matthew A. Spear, L. Candace Jennings, Henry J. Mankin, Ira J. Spiro, D S Springfield, Mark C. Gebhardt, Andrew E. Rosenberg, Jimmy T. Efird, Herman D. Suit> ;International Journal of Radiation Oncology, Biology, Physics. 1998 Feb 1
19 citations
Targeting gene therapy vectors to CNS malignancies
Matthew A Spear, Ulrich Herrlinger, Nikolai G. Rainov, Peter Pechan, Ralph Weissleder, Xandra O. Breakefield> ;Journal of Neurovirology. 1998 Jan 1
4 citations
Benign and low-grade tumors of the soft tissues: Role for radiation therapy
Herman D. Suit, Ira J. Spiro, Matthew A. Spear> ;Cancer Treatment and Research. 1997 Jan 1
Gene therapy of gliomas: receptor and transcriptional targeting.
Spear, M. A.> ;Anticancer Res. 1998 Dec 22
Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs.
Wang, Z., Tang, Z., Zheng, Y., Yu, D., Spear, M., Iyer, S. R., Bishop, B., Wu, Y.> ;Gene Ther. 2010 Sep
Join now to see all

Abstracts/Posters

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
Matthew A. Spear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

MatthewAdrianSpearMD

Dr. Spear is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.